KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Pfizer (PFE) Operating Expenses (2016 - 2026)

Pfizer has reported Operating Expenses over the past 18 years, most recently at $5.5 billion for Q1 2026.

  • Quarterly Operating Expenses fell 6.97% to $5.5 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $25.4 billion through Mar 2026, up 29.83% year-over-year, with the annual reading at $25.8 billion for FY2025, 6.38% down from the prior year.
  • Operating Expenses was $5.5 billion for Q1 2026 at Pfizer, down from $8.1 billion in the prior quarter.
  • Over five years, Operating Expenses peaked at $9.0 billion in Q4 2023 and troughed at $5.1 billion in Q2 2022.
  • The 5-year median for Operating Expenses is $6.1 billion (2022), against an average of $6.4 billion.
  • Year-over-year, Operating Expenses grew 19.64% in 2024 and then fell 22.54% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $6.3 billion in 2022, then surged by 43.37% to $9.0 billion in 2023, then tumbled by 31.47% to $6.2 billion in 2024, then soared by 32.15% to $8.1 billion in 2025, then plummeted by 32.38% to $5.5 billion in 2026.
  • Per Business Quant, the three most recent readings for PFE's Operating Expenses are $5.5 billion (Q1 2026), $8.1 billion (Q4 2025), and $6.0 billion (Q3 2025).